Last reviewed · How we verify
GSK557296 150 mg
At a glance
| Generic name | GSK557296 150 mg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Presyncope
- Nasopharyngitis
- Influenza like illness
- Oropharyngeal pain
- Nasal congestion
- Testicular pain
- Blood bilirubin increased
- Hyperaesthesia
- Fatigue
- Irritability
- Thirst
Key clinical trials
- A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation (PHASE2)
- Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing (PHASE1)
- Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |